Get the Stockscreener App
2.68
3.25%
-0.09
Entera Bio Ltd stock is traded at $2.68, with a volume of 572.83K.
It is down -3.25% in the last 24 hours and down -9.46% over the past month.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
See More
Previous Close:
$2.77
Open:
$2.72
24h Volume:
572.83K
Relative Volume:
0.68
Market Cap:
$465.88M
Revenue:
$42,000
Net Income/Loss:
$-12.38M
P/E Ratio:
-10.17
EPS:
-0.2634
Net Cash Flow:
$-9.61M
1W Performance:
+0.75%
1M Performance:
-9.46%
6M Performance:
+123.33%
1Y Performance:
+11.20%
1-Day Range:
$2.62
$2.75
1-Week Range:
$2.435
$2.82
52-Week Range:
$0.91
$4.20
Entera Bio Ltd Stock (ENTX) Company Profile
Name
Entera Bio Ltd
Sector
Industry
Phone
972-2-532-7151
Address
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
2.68 | 465.88M | 42,000 | -12.38M | -9.61M | -0.2634 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-26 | Initiated | Guggenheim | Buy |
| Sep-22-26 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-18-26 | Initiated | Leerink Partners | Outperform |
| Mar-22-21 | Initiated | Aegis Capital | Buy |
Entera Bio Ltd Stock (ENTX) Latest News
Form PRE 14A ENTERA BIO LTD. For: 27 September By Investing.com - Investing.com Australia
Form PRE 14A ENTERA BIO LTD. For: 27 September By Investing.com - Investing.com Nigeria
After raising about $275 million, Entera Bio (ENTX) asks shareholders to expand its share incentive plan. - Stock Titan
Entera Bio (Nasdaq:ENTX)Stock Analysis - Simply Wall Street
Entera Bio Stock Price Forecast. Should You Buy ENTX? - StockInvest.us
Entera Bio Ltd. WarrantADR (ENTXW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Entera Bio Ltd. WarrantADR (ENTXW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Entera Bio Ltd. WarrantADR (ENTXW) Peer Comparison – Compare with Others - Value Research
Entera Bio Ltd. SEC Filing (Aug 31, 2026) - Stock Titan
Entera to Participate in Upcoming Fall Investor Conferences - Yahoo Finance
Entera (ENTX) Earnings Reading: Reported EPS Misses Expectations on the Day; Stock Move: Shares Move Higher 5.88%Quarterly Profit Report - vinanet.vn
Entera (ENTX) Earnings Reading: Reported EPS Misses Expectations on the Day; Stock Move: Shares Move Higher 5.88%Pre-Earnings Drift - dars.gov.et
Entera (ENTX) Earnings Reading: Reported EPS Misses Expectations on the Day; Stock Move: Shares Move Higher 5.88%SaaS Earnings Trends - careplusvn.com
Entera (ENTX) Earnings Reading: Reported EPS Misses Expectations on the Day; Stock Move: Shares Move Higher 5.88%Basic EPS Analysis - dars.gov.et
Entera (ENTX) Earnings Reading: Reported EPS Misses Expectations on the Day; Stock Move: Shares Move Higher 5.88%Earnings Cycle Outlook - dars.gov.et
Entera Bio (NASDAQ:ENTX) Stock Price Up 5.1%Here's Why - MarketBeat
Entera (ENTX) Earnings Snapshot: Profit Per Share Falls Below Its Benchmark in the Reported Period - vinanet.vn
Entera (ENTX) Earnings Snapshot: Profit Per Share Falls Below Its Benchmark in the Reported Period - careplusvn.com
Entera (ENTX) Earnings Snapshot: Profit Per Share Falls Below Its Benchmark in the Reported Period - dars.gov.et
Entera (ENTX) Results Review: EPS Misses Its Estimate; Market Move: Shares Finish 4.84% Up in the Current Update - vinanet.vn
Entera Bio appoints new chief medical officer - The Globe and Mail
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Entera Bio appoints Riccardo Camisasca as chief medical officer - Investing.com
Entera Bio appoints new chief medical officer - TipRanks
Entera Bio Names New Chief Medical Officer Ahead of EB613 Phase 3 Start - Minichart
Form 8K Entera Bio Ltd. For: 18 August By Investing.com - Investing.com Nigeria
Entera Bio appoints Riccardo Camisasca as chief medical officer By Investing.com - Investing.com Canada
Entera Bio appoints Riccardo Camisasca as chief medical officer By Investing.com - Investing.com UK
Form 8K Entera Bio Ltd. For: 18 August By Investing.com - Investing.com India
Form 8K Entera Bio Ltd. For: 18 August By Investing.com - Investing.com UK
A drug developer with 30-plus years joins Entera for a planned osteoporosis Phase 3 trial - Stock Titan
Renaissance Technologies LLC Buys 365,441 Shares of Entera Bio Ltd. $ENTX - MarketBeat
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo - GlobeNewswire
Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement - MarketBeat
Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement - Yahoo Finance
Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Increases By 286.7% - MarketBeat
Entera Bio at Canaccord Genuity: oral osteoporosis push advances By Investing.com - Investing.com Canada
Entera Bio (ENTX) completes $275M Rule 506(b) private offering of shares and warrants - Stock Titan
Entera Bio Ltd (ENTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Entera Bio shares slip as Q2 loss comes in wider than expected - Yahoo Finance
Entera Bio misses Q2 estimates, reports wider loss By Investing.com - Investing.com Nigeria
Entera Bio misses Q2 estimates, reports wider loss By Investing.com - Investing.com South Africa
Entera Bio misses Q2 estimates, reports wider loss By Investing.com - Investing.com Australia
Entera Bio misses Q2 estimates, reports wider loss By Investing.com - Investing.com India
Entera Bio misses Q2 estimates, reports wider loss By Investing.com - Investing.com UK
Entera Bio misses Q2 estimates, reports wider loss - Investing.com
Entera Bio Ltd. (ENTX) stock price, news, quote and history - au.finance.yahoo.com
Entera Bio (NASDAQ:ENTX) Upgraded to Sell at Wall Street Zen - MarketBeat
Entera Bio raises $275M in oversubscribed placement, shares rebound on funding news - scanx.trade
Entera Bio Ltd Stock (ENTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Entera Bio Ltd Stock (ENTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ellis Sean | Director |
Mar 05 '26 |
Buy |
1.23 |
10,000 |
12,300 |
188,098 |
| Rubin Steven D | Director |
Feb 12 '26 |
Buy |
1.49 |
5,000 |
7,450 |
15,000 |
| Rubin Steven D | Director |
Feb 09 '26 |
Buy |
1.20 |
10,000 |
12,000 |
10,000 |
| Ellis Sean | Director |
Feb 09 '26 |
Buy |
1.24 |
18,000 |
22,320 |
178,098 |
| Toledano Miranda Jayne | Chief Executive Officer |
Dec 29 '25 |
Buy |
1.81 |
11,000 |
19,912 |
426,575 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):